Journal of Gastrointestinal Surgery

, Volume 16, Issue 6, pp 1136–1143 | Cite as

Genomic Analysis of Pterostilbene Predicts Its Antiproliferative Effects Against Pancreatic Cancer In Vitro and In Vivo

  • Denise Elizabeth McCormack
  • Patrick Mannal
  • Debbie McDonald
  • Scott Tighe
  • Joshua Hanson
  • David McFadden
2011 SSAT Poster Presentation



To investigate the inhibitory role of pterostilbene in pancreatic cancer, we conducted a genomic analysis of pterostilbene-treated pancreatic cancer cells. We also investigated the effect of pterostilbene upon the carcinogenic markers, manganese superoxide dismutase, cytochrome C, Smac/DIABLO, and STAT3 phosphorylation in vitro. The antiproliferative effects of pterostilbene were further evaluated in an in vivo model.


Pancreatic cancer cells were treated with pterostilbene and evaluated with DNA microarray analysis. Pterostilbene-treated cells were analyzed for cytochrome C, Smac/DIABLO, manganese superoxide dismutase (MnSOD)/antioxidant activity, and STAT3 phosphorylation using ELISA. Data were statistically analyzed using ANOVA. Pterostilbene was then administered to nude mice for 8 weeks, and tumor growth rates were recorded and statistically analyzed.


Microarray analysis of pterostilbene-treated cells revealed upregulation of pro-apoptosis genes. In vitro, pterostilbene treatment altered levels of phosphorylated STAT3, MnSOD/antioxidant activity, cytochrome C, and Smac/DIABLO. In nude mice, oral pterostilbene inhibited tumor growth rates.


Pterostilbene alters gene expression in pancreatic cancer and increases the antiproliferative markers cytochrome C, Smac/DIABLO, and MnSOD/antioxidant activity. It was also shown to inhibit phosphorylated STAT3, a marker of accelerated tumorigenesis, and decrease pancreatic tumor growth in vivo. Further studies are warranted to elucidate the effects of pterostilbene in humans.


Pancreatic cancer Pterostilbene Apoptosis 



Microarray analysis was conducted by the Vermont Genetics Network microarray facility through grant number 2P20RR016462 from the INBRE Program of the National Center for Research Resources (NCRR). Bioinformatic support and data analysis was conducted by Dr. Jeff Bond at the University of Vermont Bioinformatics shared resource facility.


  1. 1.
    Mannal P, Alosi J, Schneider J, et al. Pterostilbene inhibits pancreatic cancer in vitro. J Gastrointest Surg 2010. 14(5): 873–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Sharma C, Eltawil K, and Renfrew P, et al. Advances in diagnosis, treatment and palliation of pancreatic clinical carcinoma: 1990–2010. World J Gastroenterol 2011. 17(7): 867–97.PubMedCrossRefGoogle Scholar
  3. 3.
    Conroy, T, Desseigne, F, Ychou, M, et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. NEJM 2011.364:1817–1825.PubMedCrossRefGoogle Scholar
  4. 4.
    Westphal S and Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003. 2:6.Google Scholar
  5. 5.
    Cullen, J, Weydert C, Hinkhouse M, et al. The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res 2003. 63(6): 1297–303.PubMedGoogle Scholar
  6. 6.
    Ough M, Lewis A, Zhang Y, et al. Inhibition of cell growth by overexpression of manganese superoxide dismutase (MnSOD) in human pancreatic carcinoma. Free Radic Res 2004. 38(11): 1223–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Weydert C, Roling B, and Liu J, et al. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol Cancer Ther 2003. 2(4): 361–9.PubMedGoogle Scholar
  8. 8.
    Hurt E, Thomas S, Peng B, et al. Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines. Br J Cancer 2007. 97 (8): 1116–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Dineen S, Roland C, Greer R, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010. 70(7): 2852–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Huang C, Cao J, Huang KJ, et al. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro.Cancer Sci 2006.97(12):1417–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Scholz A, Heinze S, Detjen KM, et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003.125(3):891–905.PubMedCrossRefGoogle Scholar
  12. 12.
    Toyonaga T, Nakano K, Nagano M,et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 2003.201(1):107–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang M, Chen P, Dafforn, A et al. Ribo-SPIA™: A Novel Isothermal, Linear Amplification Method for Transcriptome Analysis of Very Small Samples. Macroresults for Microarrays/Genomic and Proteomic Sample Preparation, World Trade Center, Boston, Massachusetts, 2003.Google Scholar
  14. 14.
    Chen P, Deng G, Iglehart D, et al. A Novel Global mRNA Amplification Method For Gene Expression Analysis in Very Small Total RNA Samples. Molecular profiling of normal development and pathology in tissue integrating laser microdissection and microanalysis, 2002.Google Scholar
  15. 15.
    Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007. 224(3):27483.PubMedCrossRefGoogle Scholar
  16. 16.
    Roupe K, Remsberg C, Yáñez J, et al. Pharmacometrics of Stilbenes: Seguing Towards the Clinic. Curr Clin Pharmacol. Curr Clin Pharmacol 2006. 1(1): 81–101.CrossRefGoogle Scholar
  17. 17.
    Douillet-Breuil A, Jeandet P, Adrian M, et al. Changes in the phytoalexin content of various Vitis spp. in response to ultraviolet C elicitation. J Agric Food Chem 1999. 47(10): 4456–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Kapetanovic IM, Muzzio M, Huang Z, et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 2011. 68(3):593–601.PubMedCrossRefGoogle Scholar
  19. 19.
    Golkar L, Ding X, Ujiki M, et al. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res 2007. 138(2): 163–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Holtrup F, Bauer A, Fellenberg K, et al. Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br J Pharmacol 2011. 162(5):1045–59.PubMedCrossRefGoogle Scholar
  21. 21.
    Berberat PO, Dambrauskas Z, Gulbinas A, et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 2005. 11(10):3790–8.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2012

Authors and Affiliations

  • Denise Elizabeth McCormack
    • 1
  • Patrick Mannal
    • 2
  • Debbie McDonald
    • 3
  • Scott Tighe
    • 4
  • Joshua Hanson
    • 5
  • David McFadden
    • 6
  1. 1.Department of SurgeryDanbury HospitalDanburyUSA
  2. 2.Department of Surgery, Fletcher Allen Health CareUniversity of VermontBurlingtonUSA
  3. 3.Department of Surgery, Fletcher Allen Health CareUniversity of VermontBurlingtonUSA
  4. 4.Advanced Genome Technology LabUniversity of VermontBurlingtonUSA
  5. 5.Department of Pathology, Fletcher Allen Health CareUniversity of VermontBurlingtonUSA
  6. 6.University of Connecticut Health CenterFarmingtonUSA

Personalised recommendations